Table 6 shows proteins that were not detected in healthy controls and were downregulated in ERT-treated MPS IVA patients (ERT-a and/or ERT-b groups) relative to untreated patients. This evidence concerns the gene ELF3 and mucopolysaccharidosis type 4A.